Loading...
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
Angiogenesis inhibitors targeting the VEGF signaling pathway have been US FDA approved for various cancers including glioblastoma (GBM), one of the most lethal and angiogenic tumors. This has led to the routine use of the anti-VEGF antibody bevacizumab in recurrent GBM, conveying substantial improve...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Future Medicine Ltd
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673744/ https://ncbi.nlm.nih.gov/pubmed/23750318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.12.36 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|